/

KNBIF

Kane Biotech Inc.Closed

0.0172−0.00 −6.88%USD

OTC Markets OTCPK · as of Oct 13, 16:00 ET · 15m delay

Open

0.0172

Prev close

0.0185

Day range

0.01720.0172

52-week range

0.01040.0338

Volume

50.00K0.38×

Mkt cap

3.53M

P/E ttm

—

Fwd P/E

—

EPS ttm

-0.0100

Div yield

0.00%

Earnings

—

From 52w high

−49.11%

Price Chart

Yahoo Finance · delayed

KNBIFOct 13, 2026O 0.0172H 0.0172L 0.0172C 0.0172−0.0013 (−6.88%)Vol 50.00K

SMA 500.0192
SMA 2000.0229

1Y change −47.56% since Oct 13, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

KNBIF Kane Biotech Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.88%
1 month: −7.53%
3 months: −5.49%
6 months: −18.87%
Year to date: −35.34%
1 year: −47.56%

Valuation & ownership

Market cap: 3.53M
Enterprise value: 4.61M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: —
Price / sales (ttm): 91.09
EV / EBITDA: -1.75
EPS (ttm): -0.0100
EPS (forward): —
Beta (5y monthly): 0.24
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 205.06M
Float: 105.14M
Short % of float: —
Short ratio (days): —
Held by insiders: 39.82%
Held by institutions: 0.00%
Avg volume (3m): 132.12K
50-day average: 0.0192
200-day average: 0.0229
52-week change: −47.56%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 37.1
vs 50-day SMA: −10.28%
vs 200-day SMA: −24.91%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 2.84%
Realised vol (20d, ann.): 101.6%
From 52-week high: −49.11%
From 52-week low: +65.70%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 38.72K
Revenue growth (yoy): −70.90%
Earnings growth (yoy): —
Gross margin: -0.04%
Operating margin: -9633.83%
Profit margin: 0.00%

DES

About Kane Biotech Inc.

Yahoo Finance profile

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers scalp detoxifier product line under the Omni Bioceuticals brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate acne vulgaris. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Sector: Healthcare
Industry: Biotechnology
Headquarters: Winnipeg, MB, Canada
Website: kanebiotech.com
Officers: Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC Interim CEO, Director & Member of Scientific Advisory Board
Mr. Ray Dupuis Chief Financial Officer

SEAS

Seasonality · KNBIF

2007–2026 · monthly returns

Strongest month Jun +14.78%Weakest month Sep −11.55%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	10.7	-7.0	-19.7	8.6	-8.8	-3.7	-4.0	-8.2	2.7	-9.5			−35.3%
2025	1.4	-15.1	1.1	-7.6	-42.0	-2.5	-17.1	-5.8	20.1	-11.6	-13.8	6.4	−65.5%
2024	-6.7	49.0	-15.6	25.0	16.7	5.9	-11.7	14.7	-13.0	-0.8	-10.5	-11.3	+25.8%
2023	16.7	33.9	-17.0	4.7	1.9	-17.3	-2.9	-3.8	-12.3	-9.8	19.7	0.8	+2.0%
2022	-5.3	-16.9	-11.0	-16.6	-0.6	7.5	-11.3	21.0	-15.2	-9.1	-2.5	-3.8	−51.5%
2021	-12.0	6.2	20.7	42.0	-12.9	-9.5	-1.3	-7.2	8.3	-9.0	-3.8	0.5	+10.1%
2020	33.3	-14.1	-25.2	0.2	13.5	17.2	-9.2	14.7	-6.6	-18.6	26.9	-6.9	+7.0%
2019	10.1	-0.9	-23.3	-0.8	33.2	37.1	-5.2	8.8	0.6	-1.3	1.5	5.2	+65.9%
2018	0.0	-12.5	-15.6	23.3	-19.0	0.0	0.0	7.3	-21.0	32.7	8.3	-20.8	−28.8%
2017	0.0	0.0	0.0	0.0	73.7	11.3	0.0	0.0	0.0	0.0	0.0	0.0	+93.3%
2016	0.0	0.0	-3.0	-37.5	0.0	47.5	0.0	0.0	-52.2	0.0	-14.9	-23.3	−72.1%
2015	-17.5	0.0	1.8	0.3	4.7	-34.8	8.7	0.0	0.0	41.2	53.0	-38.9	−17.5%
2014	30.5	0.0	-5.3	-26.8	0.0	0.0	3.2	-2.2	-26.3	-31.8	-33.8	81.0	−45.1%
2013	0.0	82.1	8.2	-43.2	15.3	-8.9	29.9	3.9	-0.4	-37.7	15.2	-4.2	+8.7%
2012	54.6	-11.0	-13.4	-11.1	2.8	-6.8	15.9	-5.0	-11.8	0.0	0.0	0.0	−1.3%
2011	0.0	60.0	17.0	0.0	-13.4	46.0	-12.0	-22.6	-5.7	-17.2	-22.6	-18.5	−20.6%
2010	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-57.1	0.0	16.6	1.3	−47.8%
2009	4.0	-25.3	-15.0	2.6	0.0	173.3	0.0	-14.3	0.0	0.0	-36.1	82.5	+85.0%
2008	-3.4	0.0	0.0	0.0	-7.3	0.0	0.0	-48.3	-1.1	-12.6	-65.1	122.6	−68.9%
2007									-25.8	0.0	0.0	0.0	−25.8%

KNBIF

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

KNBIF

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Kane Biotech Inc.

Seasonality · KNBIF

Insider Activity · KNBIF

Congress Trades · KNBIF

Investors Holding KNBIF

Investors Holding KNBIF

Congress Trades · KNBIF

Seasonality · KNBIF

Insider Activity · KNBIF

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Kane Biotech Inc.

Earnings & Dividends

News